FDA Prioritizes Review of HIV Treatment for Newborns

ViiV Healthcare's application to expand the use of Tivicay PD for HIV treatment in newborns has received Priority Review from the FDA. The agency has set an action date of August 25, 2026, for this supplemental New Drug Application. This initiative aims to provide age-appropriate treatment options for infants living with HIV from birth.